GlassScriptPhysician profile
Rau V Bui
NPI 1891808804
$2,360.64
in general payments reported to CMS, 2019-2025
14 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $74.59 · 2021: $826 · 2022: $584 · 2023: $24.18 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $452.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.05 | 2019-2021 | |
| Amarin Pharma, INC. | $358.29 | 2019 | |
| Janssen Pharmaceuticals, INC | $237.56 | 2019-2021 | |
| Novo Nordisk INC | $231.03 | 2021-2025 | Ozempic |
| Glaxosmithkline, LLC. | $151.88 | 2022-2023 | Trelegy Ellipta |
| Edwards Lifesciences Corporation | $135.64 | 2022 | |
| Sunovion Pharmaceuticals INC. | $124.99 | 2019 | |
| Urovant Sciences INC | $116.26 | 2022 | |
| Nestle Healthcare Nutrition INC. | $52.05 | 2021 | |
| Abbvie INC. | $48.54 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $26.63 | 2021 | |
| Merck Sharp & Dohme LLC | $21.17 | 2021 | |
| Lilly USA, LLC | $17.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rau Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.